Document is current
Any future updates will be listed below
-
Authors
Ramos, Kathleen J.
Somayaji, Ranjani
Nichols, David P.
Goss, Christopher H.
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL103965, R01HL113382, UM1HL119073, U01HL114589, R01HL124053)
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK089507)
National Institutes of Health (UL1TR000423)
U.S. Food and Drug Administration (R01FD003704)
Cystic Fibrosis Foundation Therapeutics (RAMOS16A0)
Cystic Fibrosis Canada (CFCID3237)
Canadian Institutes of Health Research (201511MFE-359236-270022)
Royal College of Physicians and Surgeons (RCPSC16/DTF-08)
Grifols Pharmaceuticals
Gilead Sciences
- License Information
-
More Information
Article History
First Online: 3 August 2017
Compliance with Ethical Standards
:
: No specific funding support was received for this manuscript.
: KJR receives funding from the Cystic Fibrosis Foundation (RAMOS16A0). RS receives funding from Cystic Fibrosis Canada (CFCID3237), the Canadian Institutes for Health Research (201511MFE-359236-270022), and the Royal College of Physicians and Surgeons (RCPSC16/DTF-08). DPN receives funding from the Cystic Fibrosis Foundation and the National Institutes of Health and from NIH/National Heart, Lung, and Blood Institute (NHLBI) (R01HL124053), Cystic Fibrosis Foundation Therapeutics, Cystic Fibrosis Foundation, Grifols Pharmaceuticals, and Gilead Sciences. He has also received grant funding from Gilead Sciences and Grifols Pharmaceutics to conduct clinical and translational research, none of which is related to the topics discussed in this review. CHG has received financial support from Gilead Sciences for grant reviews and from Boehringer Ingelheim for clinical trial design consulting. CHG also receives honoraria to serve as the Chair of a Data Safety Monitoring Board for a clinical trial jointly supported by the European Commission and Novartis. CHG was also part of a research group that received a clinical research grant from Vertex Pharmaceuticals. None of this funding is related to the topics within this review. CHG receives funding from the Cystic Fibrosis Foundation, the National Institutes of Health (NIH) (R01HL103965, R01HL113382, R01AI101307, UM1HL119073, P30DK089507, UL1TR000423 U01HL114589) and the FDA (R01FD003704).
